Connection

MALCOLM BRENNER to Lymphokines

This is a "connection" page, showing publications MALCOLM BRENNER has written about Lymphokines.
Connection Strength

0.534
  1. Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
    View in: PubMed
    Score: 0.175
  2. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med. 1996 Oct; 2(10):1090-5.
    View in: PubMed
    Score: 0.135
  3. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother. 2007 Feb-Mar; 30(2):227-33.
    View in: PubMed
    Score: 0.069
  4. Non-specific factor enhancement of human in vitro antigen-dependent antibody synthesis: role of B cell activation and T cell help. Immunology. 1984 Apr; 51(4):783-91.
    View in: PubMed
    Score: 0.057
  5. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003 Mar 01; 101(5):1718-26.
    View in: PubMed
    Score: 0.051
  6. "The end of the beginning": molecular and cellular biology of gene therapy keystone. 14-20 January 1999. Biochim Biophys Acta. 1999 Jul 29; 1424(1):R5-9.
    View in: PubMed
    Score: 0.041
  7. T cell depleted bone marrow transplantation in acute myeloblastic leukaemia: the way ahead. Bone Marrow Transplant. 1989 Jan; 4 Suppl 1:225-8.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.